Vimarsana
Biggest News Aggregation in the World

Page 8 - Genetics Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Research Today - Breaking & Trending Today

New DNA testing scheme against inherited disease in Rottweilers - Vimarsana News

New DNA testing scheme against inherited disease in Rottweilers

Dogs Monthly Aiming to combat Leukoencephalomyelopathy (LEMP), an inherited disease in the Rottweiler, The Kennel Club has approved a new official DNA test reporting scheme. LEMP is a neurological disorder that affects the white matter of the central nervous system. The condition usually appears when dogs are around one to four years old; signs of LEMP include “slowly worsening problems walking, not walking in a straight line, spontaneous knuckling and dragging of the paws”. Dogs may become “increasingly immobile over a few months and their quality of life can quickly decrea...

Global DNA Data Storage Markets and Technologies Report 2021: Review the DNA Data Storage Technologies, Patents, Including DNA Read and Write Technologies - Vimarsana News

Global DNA Data Storage Markets and Technologies Report 2021: Review the DNA Data Storage Technologies, Patents, Including DNA Read and Write Technologies

Share this article Share this article ResearchAndMarkets.com's offering. The global market for DNA data storage should grow from $36.4 million in 2020 to $525.3 million by 2025 with a compound annual growth rate (CAGR) of 70.6% for the period of 2020-2025. The scope of the report includes DNA data storage technologies, applications, industries, initiatives, patents and companies. The markets for DNA data storage products and services are given for the years 2019, 2020 and 2025 (forecast). This report reviews the DNA data storage technologies, including DNA read and write technologies. It then...

Global Genes and Orphan Disease Center of the University of Pennsylvania to Convene Patient Group Leaders, Researchers, Clinicians and Industry for 6th Annual RARE Drug Development Symposium - Vimarsana News

Global Genes and Orphan Disease Center of the University of Pennsylvania to Convene Patient Group Leaders, Researchers, Clinicians and Industry for 6th Annual RARE Drug Development Symposium

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 29, 2021-- The international rare disease patient advocacy organization, Global Genes, is pleased to announce the 6th Annual RARE Drug Development Symposium (RDDS) in partnership with the Orphan Disease Center of the University of Pennsylvania. The June 9-11 virtual event will connect and educate hundreds of advocates, clinicians, and academic and industry researchers to explore the latest science, opportunities, and challenges to the advancement of therapies for more than 7,000 rare diseases. New to this year's event is an optional preconference work...

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs - Vimarsana News

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs February 15, 2021 GMT Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal BioDrugs has published results from REVEAL, the Phase I/IIa clin...

Source: apnews.com
Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021 - Vimarsana News

Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021

Press release content from Business Wire. The AP news staff was not involved in its creation. Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021 February 15, 2021 GMT Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) presented at the WORLDSymposium™ 2021 by Dr. Michaël Hocquemiller, Head of Non-Clinical Development, during the Late...

Source: apnews.com